Standard Process Veterinary Formulas, Whole Food Supplements for Small Animal and Equine Patients.
Clinical Evaluations
First Trial: Eight-Week Evaluation of Lameness
To determine the efficacy of Equine Mobility Support, clinical evaluations were conducted under the direction of a veterinarian. Horses representing different breeds, ages, and gender were evaluated prior to initiating the study to define their level of lameness. Animals having a spavin score of greater than 1 in a leg joint were recruited. Fifteen horses were enrolled in the study and were given ¼ cup (approximately 2 ounces) of Equine Mobility Support daily for 60 days. Equine participants were re-evaluated at thirty-day intervals. Change in spavin score, or lack thereof, was noted after 30 and 60 days. Serum chemistries and complete blood cell counts were performed prior to and during the study to assure no unexpected side effects developed during the study.
Figure 1: Effect of Equine Mobility Support on lameness (aggregate data)
Initial Results
All horses, with one exception, showed improvement of aggregate spavin score (total for all limbs) by 30 days (see Figure 1). At 60 days, all horses showed continued improvement. In addition, there were no actionable changes in blood chemistries.
Subjective comments from the trainers involved indicated many animals showed greater range in motion, although this wasn't measured directly.
Second Trial: Follow-up to First Trial
Eighteen additional animals were recruited for assessment. These animals were more active (dressage, endurance, jumping, therapy) and likely to exhibit different stress symptoms/indicators on their limbs. Sixteen animals finished the 60-day trial with a similar protocol. The two animals withdrawn from the study were not fed the supplement during the time the owners were on vacation. The results support those found in the initial trial (see Figure 1).
These studies contained no control group and represent the observations and measurements by the attending veterinarian.